Californian firm Synthekine, a specialist in engineered cytokine therapeutics, has agreed a global collaboration with Sanofi (Euronext: SAN).
The deal will see the companies working together to develop and commercialize interleukin (IL)-10 receptor agonists for the treatment of inflammatory diseases.
In particular, research will focus on advancing Synthekine’s multiple techniques for optimizing IL-10, with the goal of enhancing the therapeutic benefits of this approach.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze